CHA Vaccine Research Institute Logo

CHA Vaccine Research Institute

Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.

261780 | KO

Overview

Corporate Details

ISIN(s):
KR7261780001
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 둔촌대로 560, 406,407호(상대원동, 벽산테크노피아), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CHA Vaccine Research Institute is a clinical-stage biotechnology company specializing in the development of therapeutic and prophylactic vaccines and immunotherapeutics. A member of the CHA Medical and Bio Group, the company focuses on preventing and treating infectious diseases and cancer. Its core pipeline includes a third-generation hepatitis B (HBV) vaccine, a therapeutic vaccine for chronic HBV, a recombinant zoster (shingles) vaccine, and an improved influenza vaccine. The company leverages proprietary immune adjuvant platform technologies, such as L-pampo, and its own messenger RNA (mRNA) delivery system to enhance vaccine efficacy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.5 KB
2025-08-25 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 7.1 KB
2025-08-25 00:00
Board/Management Information
대표이사변경
Korean 8.9 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.0 MB
2025-08-08 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 53.2 KB
2025-07-15 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2025-07-15 00:00
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
Korean 8.0 KB
2025-07-08 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험결과) (재조합 대상포진 백신(CVI-VZV-001)의 제 1상 임상시험 결과보고서 수령)
Korean 29.2 KB
2025-06-25 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-06-20 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험결과) (만성B형간염 치료백신 CVI-HBV-002의 2b상 임상시험 결과보고서 수령)
Korean 13.8 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1007.7 KB
2025-04-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험결과) (재조합 대상포진 백신(CVI-VZV-001)의 제 1상 임상시험 Topline …
Korean 22.7 KB
2025-04-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.7 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.4 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 27.9 KB

Automate Your Workflow. Get a real-time feed of all CHA Vaccine Research Institute filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CHA Vaccine Research Institute

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CHA Vaccine Research Institute via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland
SKT
OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel
OPK
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030
Opus Genetics, Inc. Logo
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America
IRD
ORAGENICS INC Logo
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America
OGEN
Oramed Pharmaceuticals Inc. Logo
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel
ORMP

Talk to a Data Expert

Have a question? We'll get back to you promptly.